{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"0.6","value":"0.5"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"0.7","value":"0.5"},{"groupId":"OG002","lowerLimit":"0.6","upperLimit":"0.9","value":"0.6"},{"groupId":"OG003","lowerLimit":"0.5","upperLimit":"0.9","value":"0.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"111"}],"units":"Participants"}],"description":"Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"MEDIAN","populationDescription":"Randomized imatinib-resistant participants with CHR and available data were summarized.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Time to CHR in Participants With CHR at 6 Months Follow-Up","type":"SECONDARY","unitOfMeasure":"Months"}